

Strides Pharma Cyprus Ltd
Balance Sheet As on 31st Mar-22

		(Amt/EUR)	(Amt/EUR)
	Notes	Mar-21	Mar-22
Assets			
Non-current assets			
Plant and Equipment	1	27,701	19,489
Investments	2	7,373,650	7,373,650
		<u>7,401,351</u>	<u>7,393,139</u>
Current Assets			
Cash and Cash Equivalent	4	322,950	37,020
Trade and Other Receivables	3	8,536,015	11,005,191
Inventories	5	(47)	19,835
Prepayment		10,397	21,648
		<u>8,869,315</u>	<u>11,083,695</u>
Total Assets		<u>16,270,666</u>	<u>18,476,834</u>
Liabilities			
Equity	6	2,857	2,857
Monies Pending Allotment		-	-
Share premium account	7	23,624,585	23,624,585
Retained Earning	8	(10,252,402)	(7,749,768)
		<u>13,375,040</u>	<u>15,877,674</u>
Current Liabilities			
Current tax liability	9	1,019,521	1,089,320
Trade and Other Payables	10	1,876,106	1,509,840
		<u>2,895,626</u>	<u>2,599,160</u>
Total Equity and Liabilities		<u>16,270,666</u>	<u>18,476,834</u>

Strides Pharma Cyprus Ltd
Income Statement ending on 31st Mar-22

Particulars	Notes	2021	2022
		For the Year 2020-2021 YTD	For the Period 2021-2022 YTD
Revenue From Operation	11	11,432,114	14,356,046
Other Income		-	-
Total Income		11,432,114	14,356,046
Expenses			44%
Cost of Materials Consumed	12	(3,018,544)	(6,282,535)
Purchases of stock-in-trade		-	-
Changes in inventories of finished goods, stock-in-trade and work-in-progress		-	-
Employee Benefits Expense	13	(620,075)	(976,407)
Selling and Distribution Expenses	14	(769,983)	(1,025,064)
Other expenses	15	(3,396,268)	(3,534,846)
Forex Ex. Gain (Net)		(518,276)	49,709
Profit before exception, interest, depreciation and amortisation		3,108,969	2,586,903
Finance Income	16	13,205	27,669
Finance Cost	16	(53,648)	(45,096)
Net finance costs		(40,442)	(17,427)
Depreciation and Amortisation	17	(11,087)	(8,212)
Profit before exceptional items and tax		3,057,439	2,561,264
Exceptional Expenses	18	210,155	10,804
Profit before tax		3,267,594	2,572,068
Tax expense			
Current tax		-	(69,799)
Deferred tax		-	-
Total tax expense		-	(69,799)
Profit After Tax		3,267,594	2,502,269
Other comprehensive income			
Fair value gain/(loss) arising on hedging instruments		-	-
Other comprehensive income for the year net of income tax		-	-
Total comprehensive income		3,267,594	2,502,269

Strides Pharma Cyprus Ltd
Notes on Financial Statements for the period ended 31st Mar-22

Notes	Particulars	As on 31-Mar-21	As on 31-Mar-22
1	PROPERTY, PLANT AND EQUIPMENT		
	Motor Vehicles	27,701	19,489
		<u>27,701</u>	<u>19,489</u>
2	Investments		
	Non-Current		
	Investment in Subsidiary	7,373,650	7,373,650
		<u>7,373,650</u>	<u>7,373,650</u>
	Investment Gross Total	<u>7,373,650</u>	<u>7,373,650</u>
3	Trade and Other Receivables		
	Current		
	Trade Receivables	4,699,264	6,874,465
	Trade Receivables- intercompany	2,884,873	3,238,912
	Provision for Bad Debts	(629,139)	(644,929)
		<u>6,954,998</u>	<u>9,468,448</u>
	Amount Due From Related Companies	1,432,547	1,218,204
	Other Receivables	148,470	318,540
		<u>8,536,015</u>	<u>11,005,191</u>
4	Cash & Cash Equivalents		
	Cash at bank	321,658	37,020
	Cash on hand	1,292	-
		<u>322,950</u>	<u>37,020</u>
	Cash and bank bank balances	<u>322,950</u>	<u>37,020</u>
5	INVENTORY		
	Stock in trade	(47)	19,835
	Finished goods in Transit(Trading)	-	-
		<u>(47)</u>	<u>19,835</u>
	Prepayments		
	Others	10,397	21,648
		<u>10,397</u>	<u>21,648</u>
6	Share Capital		
	Fully Paid Ordinary Shares	2,857	2,857
		<u>2,857</u>	<u>2,857</u>

Strides Pharma Cyprus Ltd
Notes on Financial Statements for the period ended 31st Mar-22

Notes	Particulars	As on 31-Mar-21	As on 31-Mar-22
7	Share premium account		
	Share premium account	23,624,585	23,624,585
		<u>23,624,585</u>	<u>23,624,585</u>
8	Retained Earning		
	From Previous Years	(13,519,996)	(10,252,037)
	Current Year	3,267,594	2,502,269
		<u>(10,252,402)</u>	<u>(7,749,768)</u>
9	Current Tax Liability	<u>1,019,521</u>	<u>1,089,320</u>
10	Trade and Other Payables		
	Trade Payables	259,273	772,100
	Accruals	424,811	585,932
	Amount Due to Related Parties	1,160,912	87,845
	Other Payables	31,110	53,149
	Advance from Customers	-	10,813
		<u>1,876,106</u>	<u>1,509,840</u>

Strides Pharma Cyprus Ltd
Notes on Financial Statements for the period ended 31st Mar-22

		YTD	
Notes	Particulars	For the Period Ending on 31-Mar-21	For the Period Ending on 31-Mar-22
11	Revenue From Operation Sales of Products	11,432,114	14,356,046
		<u>11,432,114</u>	<u>14,356,046</u>
12	Cost of Materials Consumed COGS	3,018,544	6,282,535
		<u>3,018,544</u>	<u>6,282,535</u>
13	Employee Benefits Expense Staff Costs	620,075	976,407
		<u>620,075</u>	<u>976,407</u>
14	Selling and Distribution Expenses Freight Sales commission	82,511 687,472	133,110 891,954
		<u>769,983</u>	<u>1,025,064</u>
15	Other Expenses Power, fuel and water charges Rent Repair and maintenance Insurance Rates and Taxes Communication Charges Travelling and conveyance Business Promotion Support service fees Legal and professional Audit fees Regulatory fees Provision for bad debts Subcontracting charges Membership fees and subscription Others	- 5,799 25,586 4,983 1,378,569 1,321 6,977 688,708 355,282 45,160 16,795 44,275 (409,123) 1,226,809 8,681 (3,555)	- 10,377 52,255 5,562 553,376 1,255 30,347 1,058,287 395,391 26,877 10,000 88,359 (80,968) 1,336,946 45,885 897
		<u>3,396,268</u>	<u>3,534,846</u>
16	Net Finance Cost Finance Income Interest Income from Investment Bank Interest Income	13,205 -	27,669 -
		<u>13,205</u>	<u>27,669</u>
	Finance Cost Interest Expense on Loan from Immediate Holding Co Others	8,810 44,838	- 45,096
		<u>53,648</u>	<u>45,096</u>

Strides Pharma Cyprus Ltd
Notes on Financial Statements for the period ended 31st Mar-22

YTD

Notes	Particulars	For the Period Ending on 31-Mar-21	For the Period Ending on 31-Mar-22
17	Depreciation and Amortisation		
	Depreciation of PPE	10,103	8,212
	Amortization of Intangible Assets	983	-
		<u>11,087</u>	<u>8,212</u>
18	Exceptional Expenses		
	Ex Gain/Loss-Inter Co Loans & Advances	(517,117)	(27,307)
	Restructuring Cost	(3,068,076)	16,503
	Impairment of investment in Subsidiary	3,375,038	-
		<u>(210,155)</u>	<u>(10,804)</u>